Benzinga · Nov 11, 2026
TD Cowen Maintains Buy on Edwards Lifesciences, Raises Price Target to $121
TD Cowen analyst Joshua Jennings maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $117 to $121.

NYSE · EW
Healthcare · Medical - Devices
$103.88
Down-$1.35 (-1.28%)
Updated Nov 20, 2026, 2:01 AM
SID Score
7.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · EW
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
EW closed at $103.88 after 21 trading sessions, up 15.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $105.11 | $105.3425 | $103.49 | $103.88 | 3.7M |
| Nov 18, 2026 | $104.74 | $106.56 | $103.0683 | $105.23 | 3.92M |
| Nov 17, 2026 | $106.22 | $107.85 | $105.12 | $105.43 | 4.27M |
| Nov 16, 2026 | $107.00 | $108.00 | $104.94 | $107.11 | 4.54M |
| Nov 13, 2026 | $106.105 | $107.69 | $106.01 | $107.15 | 3.82M |
| Nov 12, 2026 | $106.07 | $106.80 | $104.93 | $105.80 | 4.18M |
| Nov 11, 2026 | $103.76 | $106.045 | $102.73 | $105.81 | 4.25M |
| Nov 10, 2026 | $104.25 | $104.585 | $102.43 | $104.01 | 3.78M |
| Nov 9, 2026 | $102.85 | $105.37 | $102.17 | $104.71 | 6.68M |
| Nov 6, 2026 | $99.00 | $102.19 | $98.50 | $102.14 | 5.11M |
| Nov 5, 2026 | $100.67 | $104.165 | $98.77 | $100.82 | 9.23M |
| Nov 4, 2026 | $98.58 | $100.253 | $96.72 | $99.37 | 7.9M |
| Nov 3, 2026 | $93.67 | $96.09 | $93.27 | $95.19 | 6.56M |
| Nov 2, 2026 | $93.16 | $95.75 | $87.90 | $93.26 | 12.17M |
| Oct 30, 2026 | $94.55 | $95.34 | $91.87 | $92.01 | 6.04M |
| Oct 29, 2026 | $92.63 | $95.20 | $91.995 | $94.44 | 4.68M |
| Oct 28, 2026 | $89.98 | $92.12 | $89.9001 | $91.78 | 2.3M |
| Oct 27, 2026 | $90.19 | $91.33 | $89.7301 | $90.82 | 3.02M |
| Oct 26, 2026 | $89.07 | $90.7133 | $88.91 | $90.56 | 3.33M |
| Oct 23, 2026 | $90.11 | $91.05 | $88.97 | $89.07 | 3.1M |
| Oct 22, 2026 | $88.64 | $90.19 | $88.28 | $90.09 | 3.05M |
The latest Smart Investors Daily articles mentioning EW.
Company
Market Activity
Research & News
EW research
Company profile and research snapshot.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2026 | Wells Fargo | Overweight | — |
| Nov 11, 2026 | TD Cowen | Buy | — |
| Nov 5, 2026 | Evercore ISI Group | Outperform | — |
| Nov 5, 2026 | BTIG | Buy | — |
| Nov 5, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 11, 2026
TD Cowen analyst Joshua Jennings maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $117 to $121.
Yahoo · Nov 9, 2026
Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up 0.88% at $186.42, while the S&P 500 was up 1.70% at 7,501.96. Medicare Open Enrollment is underway, and over the past week companies in pharmaceuticals, biotechnology, health insurance, medical devices and drug distribution have reported quarterly results or regulatory news. Active Companies from around the mark
Yahoo · Nov 7, 2026
Edwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations, with growth across its heart-valve businesses and regions. The medical device maker reported sales of $1.72 billion, up 11.2% from a year earlier, and adjusted
Yahoo · Nov 6, 2026
Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning EW.